Assessment of the abuse liability of synthetic cannabinoid agonists JWH-030, JWH-175, and JWH-176

Biomolecules and Therapeutics

Volumn 23, Issue 6, 2015, Pages 590-596

  Tampus, Reinholdgher ^a   Yoon, Seong Shoon ^b   de la Peña, June Bryan ^a   Botanas, Chrislean Jun ^a   Kim, Hee Jin ^a   Seo, Joung Wook ^b   Jeong, Eun Ju ^b   Jang, Choon Gon ^c   Cheong, Jae Hoon ^a  

^a Sahmyook University   (South Korea)

^b Korea Institute of Toxicology   (South Korea)

^c Sungkyunkwan University   (South Korea)

Author keywords

Abuse; Cannabis; Conditioned place preference; JWH; Self administration; Synthetic cannabinoids

Indexed keywords

CANNABINOID RECEPTOR AGONIST; JWH 030; JWH 175; JWH 176; UNCLASSIFIED DRUG;

ABSTINENCE; ABUSE LIABILITY; ANIMAL EXPERIMENT; ARTICLE; CONDITIONED PLACE PREFERENCE TEST; DRUG ABUSE; DRUG EXPOSURE; DRUG SCREENING; DRUG SELF ADMINISTRATION; DRUG STRUCTURE; LOCOMOTION; MALE; MOUSE; NONHUMAN; OPEN FIELD TEST; PLACE PREFERENCE; PSYCHOMOTOR ACTIVITY; SCORING SYSTEM;

EID: 85053361542     PISSN: 19769148     EISSN: 20054483     Source Type: Journal    
DOI: 10.4062/biomolther.2015.120     Document Type: Article

References (34)

1. Auwärter, V., Dresen, S., Weinmann, W., Müller, M., Pütz, M. and Ferreirós, N. (2009) 'Spice'and other herbal blends: harmless incense or cannabinoid designer drugs? J. Mass. Spectrom. 44, 832-837.
2. Botanas, C. J., de la Peña, J. B., dela Peña, I. J., Tampus, R., Yoon, R., Kim, H. J., Lee, Y. S., Jang, C. G. and Cheong, J. H. (2015) Methoxetamine, a ketamine derivative, produced conditioned place preference and was self-administered by rats: Evidence of its abuse potential. Pharmacol. Biochem. Behav. 133, 31-36.
3. Braida, D., Iosuè, S., Pegorini, S. and Sala, M. (2004) Δ 9-Tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats. Eur. J. Pharmacol. 506, 63-69.
4. Brents, L. K., Reichard, E. E., Zimmerman, S. M., Moran, J. H., Fantegrossi, W. E. and Prather, P. L. (2011) Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One 6. e21917
5. Chaperon, F., Soubrié, P., Puech, A. J. and Thiébot, M. H. (1998) Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology 135, 324-332.
6. Cheer, J., Kendall, D. and Marsden, C. (2000) Cannabinoid receptors and reward in the rat: a conditioned place preference study. Psychopharmacology 151, 25-30.
7. Crawley, J. N., Corwin, R. L., Robinson, J. K., Felder, C. C., Devane, W. A. and Axelrod, J. (1993) Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol. Biochem. Behav. 46, 967-972.
8. de la Peña, J. B. I., Lee, H. C., Ike, C., Woo, T. S., Yoon, S. Y., Lee, H. L., Han, J. S., Lee, J. I., Cho, Y. J. and Shin, C. Y. (2012) Rewarding and reinforcing effects of the NMDA receptor antagonist-benzodiazepine combination, zoletil®: Difference between acute and repeated exposure. Behav. Brain Res. 233, 434-442.
9. Del Arco, I., Martí, J. L., Gorriti, M. A. and Navarro, M. (1998) Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiol. Dis. 5, 483-501.
10. Drews, E., Schneider, M. and Koch, M. (2005) Effects of the cannabinoid receptor agonist WIN 55,212-2 on operant behavior and locomotor activity in rats. Pharmacol. Biochem. Behav. 80, 145-150.
11. Fadda, P., Scherma, M., Spano, M. S., Salis, P., Melis, V., Fattore, L. and Fratta, W. (2006) Cannabinoid self-administration increases dopamine release in the nucleus accumbens. Neuroreport 17, 1629-1632.
12. Fantegrossi, W. E., Moran, J. H., Radominska-Pandya, A. and Prather, P. L. (2014) Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ 9-THC: Mechanism underlying greater toxicity? Life Sci. 97, 45-54.
13. Fattore, L. and Fratta, W. (2011) Beyond THC: the new generation of cannabinoid designer drugs. Front. Behav. Neurosci. 5. 60
14. Ghozland, S., Matthes, H. W., Simonin, F., Filliol, D., Kieffer, B. L. and Maldonado, R. (2002) Motivational effects of cannabinoids are mediated by μ-opioid and κ-opioid receptors. J. Neurosci. 22, 1146-1154.
15. Golovko, A. (2011) Cannabinoids: Neurochemistry and neurobiology. Biol. Bull. Rev. 1, 526-535.
16. Gurney, S. M., Scott, K., Kacinko, S., Presley, B. and Logan, B. (2014) Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic. Sci. Rev. 26, 54-78.
17. Huestis, M. A. (2002) Cannabis(Marijuana)- effects on human behavior and performance. Forensic Sci. Rev. 14, 15-60.
18. Huffman, J. W. and Padgett, L. W. (2005) Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes. Curr. Med. Chem. 12, 1395-1411.
19. Justinova, Z., Tanda, G., Redhi, G. H. and Goldberg, S. R. (2003) Self-administration of Δ9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology 169, 135-140.
20. Maldonado, R. (2002) Study of cannabinoid dependence in animals. Pharmacol. Ther. 95, 153-164.
21. Maldonado, R. and de Fonseca, F. R. (2002) Cannabinoid addiction: behavioral models and neural correlates. J. Neurosci. 22, 3326-3331.
22. Martellotta, M., Cossu, G., Fattore, L., Gessa, G. and Fratta, W. (1998) Self-administration of the cannabinoid receptor agonist WIN 55, 212-2 in drug-naive mice. Neuroscience 85, 327-330.
23. McGregor, I. S., Issakidis, C. N. and Prior, G. (1996) Aversive effects of the synthetic cannabinoid CP 55,940 in rats. Pharmacol. Biochem. Behav. 53, 657-664.
24. Presley, B., Jansen-Varnum, S. and Logan, B. (2013) Analysis of synthetic cannabinoids in botanical material: a review of analytical methods and findings. Forensic Sci. Rev. 25, 27-46.
25. Rey, A. A., Purrio, M., Viveros, M. P. and Lutz, B. (2012) Biphasic effects of cannabinoids in anxiety responses: CB1 and GABAB receptors in the balance of GABAergic and glutamatergic neurotransmission. Neuropsychopharmacology 37, 2624-2634.
26. Sañudo-Peña, M. C., Romero, J., Seale, G. E., Fernandez-Ruiz, J. J. and Walker, J. M. (2000) Activational role of cannabinoids on movement. Eur. J. Pharmacol. 391, 269-274.
27. Schramm-Sapyta, N. L., Cha, Y. M., Chaudhry, S., Wilson, W. A., Swartzwelder, H. S. and Kuhn, C. M. (2007) Differential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats. Psychopharmacology 191, 867-877.
28. Solinas, M., Yasar, S. and Goldberg, S. R. (2007) Endocannabinoid system involvement in brain reward processes related to drug abuse. Pharmacol. Res. 56, 393-405.
29. Tai, S. and Fantegrossi, W. E. (2014) Synthetic cannabinoids: pharmacology, behavioral effects, and abuse potential. Curr. Addict. Rep. 1, 129-136.
30. Tanda, G., Munzar, P. and Goldberg, S. R. (2000) Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat. Neurosci. 3, 1073-1074.
31. Tzschentke, T. M. (2007) Review on CPP: Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict. Biol. 12, 227-462.
32. Uchiyama, N., Kikura-Hanajiri, R., Matsumoto, N., Huang, Z.-L., Goda, Y. and Urade, Y. (2012) Effects of synthetic cannabinoids on electroencephalogram power spectra in rats. Forensic Sci. Int. 215, 179-183.
33. Valjent, E., Bertran-Gonzalez, J., Aubier, B., Greengard, P., Herve, D. and Girault, J.-A. (2010) Mechanisms of locomotor sensitization to drugs of abuse in a two-injection protocol. Neuropsychopharmacology 35, 401-415
34. Valjent, E. and Maldonado, R. (2000) A behavioural model to reveal place preference to Δ9-tetrahydrocannabinol in mice. Psychopharmacology 147, 436-438.